{"database": "openregs", "table": "documents", "rows": [["FDA-2020-D-1136-0046", "FDA", "FDA-2020-D-1136", "Protecting Participants in Bioequivalence Studies for Abbreviated New Drug Applications During the COVID-19 Public Health Emergency Guidance for Industry", "Other", "Guidance", "2021-01-19T05:00:00Z", 2021, 1, "2021-01-19T05:00:00Z", "2023-05-12T03:59:59Z", "2023-05-08T18:56:13Z", null, 0, 0, "09000064849f89c5"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2020-D-1136-0046"], "units": {}, "query_ms": 100.3059180220589, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}